Atezolizumab plus chemo for extensive SCLCMay 8, 2019
Roche said the USFDA approved atezolizumab (Tecentriq), in combination with carboplatin and etoposide, for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).
This approval is based on results from the phase III IMpower133 study, which showed that atezolizumab in combination with chemotherapy helped people live significantly longer compared to chemotherapy alone.
The atezolizumab-based combination also significantly reduced the risk of disease worsening or death compared to chemotherapy alone. Safety for the atezolizumab and chemotherapy combination appeared consistent with the known safety profile of atezolizumab.
In the US, atezolizumab is approved in combination with bevacizumab, paclitaxel and carboplatin, for the first-line treatment of adults with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumour aberrations.
In Europe, the atezolizumab and bevacizumab combination is approved for the initial treatment of people with metastatic non-squamous NSCLC, including people with EGFR mutant or ALK genomic tumour aberrations after the failure of appropriate targeted therapies.
Atezolizumab is also approved by the FDA to treat adults with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy.
IMpower133 is a phase III, multicentre, double-blinded, randomised placebo-controlled study evaluating the efficacy and safety of atezolizumab in combination with chemotherapy vs. chemotherapy vs. chemotherapy alone in chemotherapy-naïve adults with ES-SCLC.
Atezolizumab is a monoclonal antibody designed to bind with a protein called PD-L1 expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors.